FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 90960

Company■ Mixed

New Phase 3 trial: A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults — Pfizer

KINDCompany
DIRECTION■ Mixed
SOURCES1
ENTITIES0
STORY SIZESTANDALONE
FIRST SEEN
LAST UPDATE
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

THE MACHINE IS STILL READING THIS ITEM — ANALYSIS LANDS WITHIN MINUTES OF INGESTION.

FULL DISPATCH

Sponsor: Pfizer; Status: Not Yet Recruiting; Conditions: Respiratory Syncytial Virus (RSV); Interventions: RSVpreF (Regimen A), RSVpreF (Regimen B); Enrollment: 750 (estimated); First posted: 2026-10-21; NCT: NCT07885956

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

NO ENTITY LINKS AT DISPLAY CONFIDENCE YET.

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01clinicaltrialsclinicaltrials.gov · PRIMARY2026-10-21 12:00 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

←INFERENCEfilings generate company commentary
META filed 8-K on 2026-10-21
2026-10-21 00:00 UTC
←INFERENCEfilings generate company commentary
NFLX filed 10-Q on 2026-10-21
2026-10-21 00:00 UTC
←INFERENCEfilings generate company commentary
TSLA filed 8-K on 2026-10-21
2026-10-21 00:00 UTC
←INFERENCEfilings generate company commentary
CVX filed 4 on 2026-10-21
2026-10-21 00:00 UTC
←INFERENCEfilings generate company commentary
JNJ filed 10-Q on 2026-10-21
2026-10-21 00:00 UTC
←INFERENCEfilings generate company commentary
META filed 4 on 2026-10-21
2026-10-21 00:00 UTC

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.